Literature DB >> 23340442

Collagen binding provides a sensitive screen for variant von Willebrand disease.

Veronica H Flood1, Joan Cox Gill, Kenneth D Friedman, Pamela A Christopherson, Paula M Jacobi, Raymond G Hoffmann, Robert R Montgomery, Sandra L Haberichter.   

Abstract

BACKGROUND: von Willebrand factor (VWF) is a multimeric protein that binds platelets and collagen, facilitating hemostasis at sites of vessel injury. Measurement of VWF multimer distribution is critical for diagnosis of variant von Willebrand disease (VWD), particularly types 2A and 2B, but the typical measurement by gel electrophoresis is technically difficult and time-consuming. A comparison of VWF collagen binding (VWF:CB) and VWF multimer distribution was performed to evaluate the utility of VWF:CB as a diagnostic test.
METHODS: Participants were enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD. VWF:CB was analyzed with type III collagen and multimer distribution by agarose gel electrophoresis. The study population included 146 healthy controls, 351 individuals with type 1 VWD, and 77 with type 2 VWD. Differences between individuals with multimer group results within (controls) and outside the reference intervals were assessed with Mann-Whitney tests.
RESULTS: The mean VWF:CB/VWF antigen ratio was 1.10 for individuals with multimer distribution within the reference intervals and 0.51 for those with multimer distribution outside the reference intervals (P < 0.001). Sensitivity of VWF:CB for multimer abnormalities was 100% for healthy controls, 99% for patients with type 1, and 100% for patients with type 2A and type 2B VWD using a VWF:CB/VWF antigen cutoff ratio of 0.6, and decreased to 99% for all patients with a ratio of 0.7. With the exception of individuals with novel or unclassified mutations, the VWF:CB was able to correctly categorize participants with variant VWD.
CONCLUSIONS: These findings suggest that VWF:CB may substitute for multimer distribution in initial VWD testing, although further studies are needed to validate the clinical utility of VWF:CB.
© 2012 American Association for Clinical Chemistry

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340442      PMCID: PMC3852672          DOI: 10.1373/clinchem.2012.199000

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  33 in total

1.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).

Authors:  A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  A novel candidate mutation (Arg611-->His) in type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia.

Authors:  G Castaman; J C Eikenboom; F Rodeghiero; E Briët; P H Reitsma
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

3.  Diagnosing von Willebrand disease: a large reference laboratory's perspective.

Authors:  Dorothy M Adcock; Melissa Bethel; Andre Valcour
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

4.  An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.

Authors:  Piet Meijer; Frits Haverkate
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

5.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.

Authors:  J C Gill; A D Wilson; J Endres-Brooks; R R Montgomery
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

Review 7.  Regulated release of VWF and FVIII and the biologic implications.

Authors:  S L Haberichter; Q Shi; R R Montgomery
Journal:  Pediatr Blood Cancer       Date:  2006-05-01       Impact factor: 3.167

8.  Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms.

Authors:  E J Favaloro; D Facey; L Grispo
Journal:  Am J Clin Pathol       Date:  1995-09       Impact factor: 2.493

9.  A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity.

Authors:  R R Montgomery; W E Hathaway; J Johnson; L Jacobson; W Muntean
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

10.  Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF.

Authors:  L Hilbert; C Gaucher; C Mazurier
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more
  16 in total

1.  Crucial role for the VWF A1 domain in binding to type IV collagen.

Authors:  Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

2.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 3.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

Review 4.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

5.  New advances in the diagnosis of von Willebrand disease.

Authors:  Ruchika Sharma; Sandra L Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

7.  Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.

Authors:  M Lehmann; K Ashworth; M Manco-Johnson; J Di Paola; K B Neeves; C J Ng
Journal:  J Thromb Haemost       Date:  2017-11-23       Impact factor: 5.824

Review 8.  Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.

Authors:  Brian R Branchford; Christopher J Ng; Keith B Neeves; Jorge Di Paola
Journal:  Thromb Res       Date:  2015-05-21       Impact factor: 3.944

9.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

Review 10.  Microfluidic devices for studying coagulation biology.

Authors:  Brady M Trevisan; Christopher D Porada; Anthony Atala; Graça Almeida-Porada
Journal:  Semin Cell Dev Biol       Date:  2020-06-18       Impact factor: 7.499

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.